Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1994 Aug;82(4):516–521.

Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors.

M Oppermann 1, O Götze 1
PMCID: PMC1414921  PMID: 7835913

Abstract

The C5a anaphylatoxin is a potent complement-derived mediator of inflammation with chemotactic activity. In this study the possible role of specific high-affinity binding sites for C5a on peripheral blood leucocytes for the removal of C5a from human blood plasma was investigated. The addition of purified granulocytes or mononuclear cells to complement-activated plasma resulted in the rapid and dose-dependent removal of up to 80% of plasma C5a, as determined by ELISA. The specific role of leucocyte C5a receptors (C5aR) in the plasma clearance of C5a was demonstrated by the inhibition of C5a uptake by the preincubation of cells with the C5aR-specific monoclonal antibody S5/1. Furthermore, U937 cells which had been induced by db-cAMP to express C5aR, but not undifferentiated U937 cells, were capable of removing C5a from plasma. The inhibition of C5aR internalization by monensin did not affect C5a uptake by leucocytes. The co-incubation with leucocytes had no effect on the plasma clearance of complement activation products C3a or terminal complement complex (TCC), as determined by this in vitro assay. The binding of the C5a anaphylatoxin to cellular receptors represents an effective control mechanism that protects the organism from systemic effects of this potent phlogistic mediator.

Full text

PDF
516

Images in this article

518Figure 2
on p.518

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barker M. D., Jose P. J., Williams T. J., Burton D. R. The chemoattractant des-Arg74-C5a regulates the expression of its own receptor on a monocyte-like cell line. Biochem J. 1986 Jun 1;236(2):621–624. doi: 10.1042/bj2360621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bingel M., Arndt W., Schulze M., Floege J., Shaldon S., Koch K. M., Götze O. Comparative study of C5a plasma levels with different hemodialysis membranes using an enzyme-linked immunosorbent assay. Nephron. 1989;51(3):320–324. doi: 10.1159/000185316. [DOI] [PubMed] [Google Scholar]
  3. Bokisch V. A., Müller-Eberhard H. J. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest. 1970 Dec;49(12):2427–2436. doi: 10.1172/JCI106462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chenoweth D. E. Anaphylatoxin formation in extracorporeal circuits. Complement. 1986;3(3):152–165. doi: 10.1159/000467892. [DOI] [PubMed] [Google Scholar]
  5. Craddock P. R., Fehr J., Dalmasso A. P., Brighan K. L., Jacob H. S. Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest. 1977 May;59(5):879–888. doi: 10.1172/JCI108710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Elsner J., Oppermann M., Czech W., Kapp A. C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins. Blood. 1994 Jun 1;83(11):3324–3331. [PubMed] [Google Scholar]
  7. Fukuoka Y., Hugli T. E. Anaphylatoxin binding and degradation by rat peritoneal mast cells. Mechanisms of degranulation and control. J Immunol. 1990 Sep 15;145(6):1851–1858. [PubMed] [Google Scholar]
  8. Gerardy-Schahn R., Ambrosius D., Saunders D., Casaretto M., Mittler C., Karwarth G., Görgen S., Bitter-Suermann D. Characterization of C3a receptor-proteins on guinea pig platelets and human polymorphonuclear leukocytes. Eur J Immunol. 1989 Jun;19(6):1095–1102. doi: 10.1002/eji.1830190620. [DOI] [PubMed] [Google Scholar]
  9. Huey R., Hugli T. E. Characterization of a C5a receptor on human polymorphonuclear leukocytes (PMN). J Immunol. 1985 Sep;135(3):2063–2068. [PubMed] [Google Scholar]
  10. Jesaitis R. K., Dahinden C. A., Chang C. M., Jesaitis A. J. Investigations on the role of Golgi-mediated, ligand-receptor processing in the activation of granulocytes by chemoattractants: differential effects of monensin. Biochim Biophys Acta. 1987 Mar 11;927(3):382–391. doi: 10.1016/0167-4889(87)90103-0. [DOI] [PubMed] [Google Scholar]
  11. Klos A., Bank S., Gietz C., Bautsch W., Köhl J., Burg M., Kretzschmar T. C3a receptor on dibutyryl-cAMP-differentiated U937 cells and human neutrophils: the human C3a receptor characterized by functional responses and 125I-C3a binding. Biochemistry. 1992 Nov 24;31(46):11274–11282. doi: 10.1021/bi00161a003. [DOI] [PubMed] [Google Scholar]
  12. Mousli M., Hugli T. E., Landry Y., Bronner C. A mechanism of action for anaphylatoxin C3a stimulation of mast cells. J Immunol. 1992 Apr 15;148(8):2456–2461. [PubMed] [Google Scholar]
  13. Oppermann M., Haubitz M., Quentin E., Götze O. Complement activation in patients with renal failure as detected through the quantitation of fragments of the complement proteins C3, C5, and factor B. Klin Wochenschr. 1988 Sep 15;66(18):857–864. doi: 10.1007/BF01728947. [DOI] [PubMed] [Google Scholar]
  14. Oppermann M., Höpken U., Götze O. Assessment of complement activation in vivo. Immunopharmacology. 1992 Sep-Oct;24(2):119–134. doi: 10.1016/0162-3109(92)90018-8. [DOI] [PubMed] [Google Scholar]
  15. Oppermann M., Raedt U., Hebell T., Schmidt B., Zimmermann B., Götze O. Probing the human receptor for C5a anaphylatoxin with site-directed antibodies. Identification of a potential ligand binding site on the NH2-terminal domain. J Immunol. 1993 Oct 1;151(7):3785–3794. [PubMed] [Google Scholar]
  16. Plummer T. H., Jr, Ryan T. J. A potent mercapto bi-product analogue inhibitor for human carboxypeptidase N. Biochem Biophys Res Commun. 1981 Jan 30;98(2):448–454. doi: 10.1016/0006-291x(81)90860-3. [DOI] [PubMed] [Google Scholar]
  17. Swerlick R. A., Yancey K. B., Lawley T. J. A direct in vivo comparison of the inflammatory properties of human C5a and C5a des Arg in human skin. J Immunol. 1988 Apr 1;140(7):2376–2381. [PubMed] [Google Scholar]
  18. Tardif M., Mery L., Brouchon L., Boulay F. Agonist-dependent phosphorylation of N-formylpeptide and activation peptide from the fifth component of C (C5a) chemoattractant receptors in differentiated HL60 cells. J Immunol. 1993 Apr 15;150(8 Pt 1):3534–3545. [PubMed] [Google Scholar]
  19. Van Epps D. E., Simpson S. J., Chenoweth D. E. C5a and formyl peptide receptor regulation on human monocytes. J Leukoc Biol. 1992 Apr;51(4):393–399. doi: 10.1002/jlb.51.4.393. [DOI] [PubMed] [Google Scholar]
  20. Van Epps D. E., Simpson S., Bender J. G., Chenoweth D. E. Regulation of C5a and formyl peptide receptor expression on human polymorphonuclear leukocytes. J Immunol. 1990 Feb 1;144(3):1062–1068. [PubMed] [Google Scholar]
  21. Webster R. O., Larsen G. L., Henson P. M. In vivo clearance and tissue distribution of C5a and C5a des arginine complement fragments in rabbits. J Clin Invest. 1982 Dec;70(6):1177–1183. doi: 10.1172/JCI110716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Weisdorf D. J., Hammerschmidt D. E., Jacob H. S., Craddock P. R. Rapid in vivo clearance of C5ades arg: a possible protective mechanism against complement-mediated tissue injury. J Lab Clin Med. 1981 Dec;98(6):823–830. [PubMed] [Google Scholar]
  23. Werfel T., Sonntag G., Weber M. H., Götze O. Rapid increases in the membrane expression of neutral endopeptidase (CD10), aminopeptidase N (CD13), tyrosine phosphatase (CD45), and Fc gamma-RIII (CD16) upon stimulation of human peripheral leukocytes with human C5a. J Immunol. 1991 Dec 1;147(11):3909–3914. [PubMed] [Google Scholar]
  24. Würzner R., Schulze M., Happe L., Franzke A., Bieber F. A., Oppermann M., Götze O. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm. 1991;8(5-6):328–340. doi: 10.1159/000463204. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES